Chambers Duncan, Preston Louise, Clowes Mark, Cantrell Anna J, Goyder Elizabeth C
Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK
Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
BMJ Open. 2024 Aug 7;14(8):e081934. doi: 10.1136/bmjopen-2023-081934.
To systematically review and synthesise evidence on the effectiveness and implementation barriers/facilitators of pharmacist-led interventions to promote medicines optimisation and reduce overprescribing in UK primary care.
Systematic review.
UK primary care.
We searched MEDLINE, Embase, CINAHL PsycINFO and The Cochrane Library for UK-based studies published between January 2013 and February 2023. Targeted searches for grey literature were conducted in May 2023. Quantitative and qualitative studies (including conference abstracts and grey literature) that addressed a relevant intervention and reported a primary outcome related to changes in prescribing were eligible for inclusion. Quality of included studies was assessed using the Multiple Methods Appraisal Tool. We performed a narrative synthesis, grouping studies by publication status, setting and type of data reported (effectiveness or implementation).
We included 14 peer-reviewed journal articles and 11 conference abstracts, together with 4 case study reports. The journal articles reported 10 different interventions, 5 delivered in general practice, 4 in care homes and 1 in community pharmacy. The quality of evidence was higher in general practice than in care home settings. It was consistently reported that the intervention improved outcomes related to prescribing, although the limited number of studies and wide range of outcomes reported made it difficult to estimate the size of any effect. Implementation was strongly influenced by relationships between pharmacists and other health and care professionals, especially general practitioners. Implementation in care homes appeared to be more complex than in general practice because of differences in systems and 'culture' between health and social care.
Pharmacist-led interventions have been reported to reduce overprescribing in primary care settings in the UK but a shortage of high-quality evidence means that more rigorous studies using high-quality designs are needed. More research is also needed in community pharmacy settings; to assess intervention effects on patient outcomes other than prescribing and to investigate how reducing overprescribing can impact health inequalities.
CRD42023396366.
系统评价并综合有关药剂师主导的干预措施在促进英国初级保健中药物优化和减少过度开药方面的有效性及实施障碍/促进因素的证据。
系统评价。
英国初级保健。
我们检索了MEDLINE、Embase、CINAHL、PsycINFO和Cochrane图书馆,查找2013年1月至2023年2月发表的基于英国的研究。2023年5月对灰色文献进行了针对性检索。涉及相关干预措施并报告了与处方变化相关的主要结局的定量和定性研究(包括会议摘要和灰色文献)均符合纳入标准。使用多方法评估工具评估纳入研究的质量。我们进行了叙述性综合分析,按发表状态、背景和报告的数据类型(有效性或实施情况)对研究进行分组。
我们纳入了14篇同行评审的期刊文章、11篇会议摘要以及4篇案例研究报告。期刊文章报告了10种不同的干预措施,5种在全科医疗中实施,4种在护理院中实施,1种在社区药房中实施。全科医疗中的证据质量高于护理院环境。一致报告称该干预措施改善了与处方相关的结局,尽管研究数量有限且报告的结局范围广泛,难以估计任何效果的大小。实施情况受到药剂师与其他健康和护理专业人员之间关系的强烈影响,尤其是与全科医生的关系。由于健康和社会护理之间的系统和“文化”差异,护理院的实施似乎比全科医疗更为复杂。
据报道,在英国初级保健环境中,药剂师主导的干预措施可减少过度开药,但高质量证据的缺乏意味着需要采用高质量设计进行更严格的研究。社区药房环境中也需要更多研究;评估干预措施对除处方外的患者结局的影响,并调查减少过度开药如何影响健康不平等问题。
PROSPERO注册号:CRD42023396366。